Recent Posts

• The Food and Drug Administration (FDA) issues a favorable opinion on the preclinical development plan submitted by Theranexus and BBDF
• Presentation of the results of the phase IB Clinical study of THN201 for Alzheimer’s disease at the clinical trials on Alzheimer’s disease conference (CTAD)
• Theranexus et BBDF obtain European “orphan medicinal product” designation for BBDF-101 in Batten disease
• Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, for Hypoparathyroidism
• Theranexus presents its latest scientific news